- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy ; volume:269 ; number:1 ; day:8 ; month:12 ; year:2021 ; pages:534-536 ; date:1.2022
Journal of neurology ; 269, Heft 1 (8.12.2021), 534-536, 1.2022
- Urheber
-
Talaei, M.
Robertson, N. P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-021-10908-9
- URN
-
urn:nbn:de:101:1-2022042407335524653382
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Talaei, M.
- Robertson, N. P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy